Study of AFP464 +/- Faslodex in ER + Breast Cancer

NCT01233947 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasm

Interventions

DRUG: AFP464
DRUG: AFP464 + Faslodex

Sponsor

Tigris Pharmaceuticals